Approval · Notice of Compliance 18737 · 2016
BAT: Notice of Compliance 18737
Issued December 8, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18737
- Date
- December 8, 2016
- Company
- Cangene Corporation
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BAT | 02459612 | Restricted Access |
Medicinal ingredients
- BOTULINUM ANTITOXIN SEROTYPE A 4,500 UNIT per VIAL
- BOTULINUM ANTITOXIN SEROTYPE B 3,300 UNIT per VIAL
- BOTULINUM ANTITOXIN SEROTYPE C 3,000 UNIT per VIAL
- BOTULINUM ANTITOXIN SEROTYPE D 600 UNIT per VIAL
- BOTULINUM ANTITOXIN SEROTYPE E 5,100 UNIT per VIAL
- BOTULINUM ANTITOXIN SEROTYPE F 3,000 UNIT per VIAL
- BOTULINUM ANTITOXIN SEROTYPE G 600 UNIT per VIAL